Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project
Sandra Heesch(BioNTech (Germany)), Uğur Şahin(Johannes Gutenberg University Mainz), Sebastian Kreiter(Johannes Gutenberg University Mainz), Tobias Sjöblom(Uppsala University), Alexandra Kemmer-Brueck(BioNTech (Germany)), Klaus Kuehlcke, Oezlem Tuereci(Uppsala University Hospital), Doreen Schwarck-Kokarakis(BioNTech (Germany)), Sebastian Petri(BioNTech (Germany)), Cedrik M. Britten(Johannes Gutenberg University Mainz), Anna Paruzynski(BioNTech (Germany)), Katrin Frenzel(Uppsala University Hospital), Marcus Schmidt(Johannes Gutenberg University Mainz), Thomas Kuendig(University Hospital Zurich), Henrik Lindman(Uppsala University), Heinrich Haas(BioNTech (Germany)), Burkhard Otte(BioNTech (Germany)), Laurence Zitvogel(Institut Gustave Roussy), Bjoern-Philipp Kloke(BioNTech (Germany)), Martin Löewer(Uppsala University Hospital), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, John Castle, Jacques De Grève(Vrije Universiteit Brussel), Jan Diekmann(BioNTech (Germany)), Steve Pascolo(University of Zurich), Kris Thielemans(Vrije Universiteit Brussel), Fabrice André(Inserm), Janina Buck(BioNTech (Germany)), Andreas N. Kuhn(Uppsala University Hospital)
Cited by 1
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k